The results indicated that the expression of CD274, CTLA4, PDCD1, and LAG3 in the samples of the high-risk group was significantly higher than that of the low-risk group, suggesting that the high expression of relevant genes might be one of the reasons that affected GBM treatment efficacy (Supplementary Figure S6F–I). This evidence concerns the gene CD274 and glioblastoma.